Overview
- Viking is running a phase 3 study of VK2735 in an injectable formulation for weight loss.
- The company says it plans to begin a phase 3 trial of an oral version later this year.
- Yahoo Finance’s analysis argues the stock could rise tenfold if the obesity pipeline secures approvals and commercial traction.
- Viking’s market value is about $3.5 billion, leaving room to expand if products reach the market and generate revenue.
- Demand for GLP-1 weight-loss drugs has been strong, at times exceeding supply before manufacturers ramped output, which supports the case for additional competitors.